144 related articles for article (PubMed ID: 18955441)
1. Targeting polo-like kinase: learning too little too late?
Olmos D; Swanton C; de Bono J
J Clin Oncol; 2008 Dec; 26(34):5497-9. PubMed ID: 18955441
[No Abstract] [Full Text] [Related]
2. Discovery of thiophene inhibitors of polo-like kinase.
Emmitte KA; Andrews CW; Badiang JG; Davis-Ward RG; Dickson HD; Drewry DH; Emerson HK; Epperly AH; Hassler DF; Knick VB; Kuntz KW; Lansing TJ; Linn JA; Mook RA; Nailor KE; Salovich JM; Spehar GM; Cheung M
Bioorg Med Chem Lett; 2009 Feb; 19(3):1018-21. PubMed ID: 19097784
[TBL] [Abstract][Full Text] [Related]
3. Polo and Aurora kinases: lessons derived from chemical biology.
Taylor S; Peters JM
Curr Opin Cell Biol; 2008 Feb; 20(1):77-84. PubMed ID: 18249108
[TBL] [Abstract][Full Text] [Related]
4. Identification of novel polo-like kinase 1 inhibitors by a hybrid virtual screening.
Lu S; Sun SL; Liu HC; Chen YD; Yuan HL; Gao YP; Yang P; Lu T
Chem Biol Drug Des; 2012 Aug; 80(2):328-39. PubMed ID: 22583481
[TBL] [Abstract][Full Text] [Related]
5. PLK1 inhibitors: setting the mitotic death trap.
Plyte S; Musacchio A
Curr Biol; 2007 Apr; 17(8):R280-3. PubMed ID: 17437704
[TBL] [Abstract][Full Text] [Related]
6. PLK1 as an oncology target: current status and future potential.
McInnes C; Wyatt MD
Drug Discov Today; 2011 Jul; 16(13-14):619-25. PubMed ID: 21601650
[TBL] [Abstract][Full Text] [Related]
7. Heteroaryl-linked 5-(1H-benzimidazol-1-yl)-2-thiophenecarboxamides: potent inhibitors of polo-like kinase 1 (PLK1) with improved drug-like properties.
Rheault TR; Donaldson KH; Badiang-Alberti JG; Davis-Ward RG; Andrews CW; Bambal R; Jackson JR; Cheung M
Bioorg Med Chem Lett; 2010 Aug; 20(15):4587-92. PubMed ID: 20594842
[TBL] [Abstract][Full Text] [Related]
8. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity.
Rudolph D; Steegmaier M; Hoffmann M; Grauert M; Baum A; Quant J; Haslinger C; Garin-Chesa P; Adolf GR
Clin Cancer Res; 2009 May; 15(9):3094-102. PubMed ID: 19383823
[TBL] [Abstract][Full Text] [Related]
9. Pinning down the polo-box domain.
Lee KS; Idle JR
Chem Biol; 2008 May; 15(5):415-6. PubMed ID: 18482691
[TBL] [Abstract][Full Text] [Related]
10. Design of potent thiophene inhibitors of polo-like kinase 1 with improved solubility and reduced protein binding.
Emmitte KA; Adjabeng GM; Andrews CW; Alberti JG; Bambal R; Chamberlain SD; Davis-Ward RG; Dickson HD; Hassler DF; Hornberger KR; Jackson JR; Kuntz KW; Lansing TJ; Mook RA; Nailor KE; Pobanz MA; Smith SC; Sung CM; Cheung M
Bioorg Med Chem Lett; 2009 Mar; 19(6):1694-7. PubMed ID: 19237286
[TBL] [Abstract][Full Text] [Related]
11. Minting a new class of polo-like-kinase inhibitors.
Dent P; Curiel DT; Grant S; Fisher PB
Cancer Biol Ther; 2009 Dec; 8(24):2384-5. PubMed ID: 20009506
[No Abstract] [Full Text] [Related]
12. Imidazopyridine derivatives as potent and selective Polo-like kinase (PLK) inhibitors.
Sato Y; Onozaki Y; Sugimoto T; Kurihara H; Kamijo K; Kadowaki C; Tsujino T; Watanabe A; Otsuki S; Mitsuya M; Iida M; Haze K; Machida T; Nakatsuru Y; Komatani H; Kotani H; Iwasawa Y
Bioorg Med Chem Lett; 2009 Aug; 19(16):4673-8. PubMed ID: 19589677
[TBL] [Abstract][Full Text] [Related]
13. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
14. Imidazo[5,1-f][1,2,4]triazin-2-amines as novel inhibitors of polo-like kinase 1.
Cheung M; Kuntz KW; Pobanz M; Salovich JM; Wilson BJ; Andrews CW; Shewchuk LM; Epperly AH; Hassler DF; Leesnitzer MA; Smith JL; Smith GK; Lansing TJ; Mook RA
Bioorg Med Chem Lett; 2008 Dec; 18(23):6214-7. PubMed ID: 18929484
[TBL] [Abstract][Full Text] [Related]
15. Developing polo-like kinase 1 inhibitors.
Huang X; Xie Z; Liao C
Future Med Chem; 2020 May; 12(10):869-871. PubMed ID: 32233804
[No Abstract] [Full Text] [Related]
16. Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
Fucini RV; Hanan EJ; Romanowski MJ; Elling RA; Lew W; Barr KJ; Zhu J; Yoburn JC; Liu Y; Fahr BT; Fan J; Lu Y; Pham P; Choong IC; VanderPorten EC; Bui M; Purkey HE; Evanchik MJ; Yang W
Bioorg Med Chem Lett; 2008 Oct; 18(20):5648-52. PubMed ID: 18793847
[TBL] [Abstract][Full Text] [Related]
17. Drugs by numbers: reaction-driven de novo design of potent and selective anticancer leads.
Spänkuch B; Keppner S; Lange L; Rodrigues T; Zettl H; Koch CP; Reutlinger M; Hartenfeller M; Schneider P; Schneider G
Angew Chem Int Ed Engl; 2013 Apr; 52(17):4676-81. PubMed ID: 23166089
[TBL] [Abstract][Full Text] [Related]
18. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis.
Reindl W; Yuan J; Krämer A; Strebhardt K; Berg T
Chembiochem; 2009 May; 10(7):1145-8. PubMed ID: 19350612
[TBL] [Abstract][Full Text] [Related]
19. Polo-like kinase (Plk) 1 as a target for prostate cancer management.
Reagan-Shaw S; Ahmad N
IUBMB Life; 2005 Oct; 57(10):677-82. PubMed ID: 16223707
[TBL] [Abstract][Full Text] [Related]
20. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo.
Steegmaier M; Hoffmann M; Baum A; Lénárt P; Petronczki M; Krssák M; Gürtler U; Garin-Chesa P; Lieb S; Quant J; Grauert M; Adolf GR; Kraut N; Peters JM; Rettig WJ
Curr Biol; 2007 Feb; 17(4):316-22. PubMed ID: 17291758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]